Verified Rigor RecordRigor Reviewed

Rigor-Reviewed Manuscript

Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease · 10.1371/journal.pone.0019338

Name: Verified Rigor Record — Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease · 10.1371/journal.pone.0019338
Item: Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease · 10.1371/journal.pone.0019338
Rating: 75
Author: Αlpha¹

Paper source

Read full text

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · July 6, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

WARN

Warnings to address · Interventional Study

Eight dimensions — click a segment for details

Critical

High-priority

Model-reported confidence: moderateReviewer agreement: lowEngine: 7.6.0Source: full text

Not verified in this report

No reported statistical tests were found to recompute.
No data or code availability links were detected to verify.

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This preclinical passive immunization study has a well-founded scientific premise and clear ethics approval, but substantial gaps in reporting of study design, biological variables, key resources, statistical analysis, and data availability severely limit its robustness. Two retracted citations are also present. The copyedit issues are minor but the rigor deficiencies are major concerns for a published work.

Three independent reviewers evaluated the full published text. There was agreement on scientific premise, ethical approvals, and reporting transparency. Divergence occurred on study design, biological variables, key resources, statistical analysis, and data/code availability, where one reviewer rated stricter than the others; the synthesized verdicts here follow the checklist-based scoring rules, which yield 'fail' on those dimensions. The statistics verification component could not recompute any reported tests (no test statistics with dfs were provided). Two retracted references were identified. No reproducibility assessment was performed.

12 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).

Rigor

Eight Dimensions2 pass · 6 warn

12 major claims1 overstated2 partial9 supported

The introduction comprehensively reviews literature on α-synuclein aggregation, its role in LBD, and previous immunotherapy attempts. It cites both strengths of prior work (e.g., active immunization efficacy) and gaps (e.g., need for widespread therapeutic approaches). The rationale for passive immunization with a C-terminal antibody is logically derived from this evidence. Limitations of prior approaches, such as gene therapy targeting only selective regions, are acknowledged and addressed by the broader approach of immunotherapy.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific foundation by citing prior work on α-synuclein aggregation and immunotherapy, providing a logical rationale, and addressing limitations of earlier approaches.

Evidence

direct quote[Introduction, paragraph 2]

“Previous studies have shown that intracellular antibodies (intrabodies) can inhibit α-syn aggregation, and that copolymer-1 immunotherapy reduces neurodegeneration in a PD model.”

direct quote[Introduction, paragraph 3]

“This study examined whether passive immunization with an antibody against the C-terminus (CT) of α-syn (hereafter referred to as the 9E4 antibody) was able to recognize and clear a-syn aggregates in a-syn tg mice.”

direct quote[Introduction, paragraph 2]

“However, neurodegenerative processes in LBD are more widespread than originally suspected therefore there is a need for therapeutic approaches that target toxic α-syn in multiple neuronal populations simultaneously.”

PASSReviewer 2· 95% conf

The scientific premise is well-established through extensive citation of prior work on α-synuclein in Lewy body disease and immunotherapy, with a clear rationale linking the premise to the study's objectives.

Evidence

direct quote[Introduction]

“Previous studies have used gene therapy targeting selective regions to increase α-syn clearance via autophagy or by reducing α-syn synthesis. However, neurodegenerative processes in LBD are more widespread than originally suspected therefore there is a need for therapeutic approaches that target toxic α-syn in multiple neuronal populations simultaneously. For this reason we began to explore an immunotherapy approach for LBD and have previously shown that active immunization with recombinant α-syn ameliorates α-syn related synaptic pathology in a transgenic (tg) mouse model of PD.”

direct quote[Introduction]

PASSReviewer 3· 95% conf

The paper adequately establishes the scientific premise for passive immunization against alpha-synuclein in Lewy body disease.

Evidence

direct quote[Introduction, paragraphs 1-3]

“we began to explore an immunotherapy approach for LBD and have previously shown that active immunization with recombinant α-syn ameliorates α-syn related synaptic pathology in a transgenic (tg) mouse model of PD.”

direct quote[Introduction, final paragraph]

direct quote[Introduction, paragraph 2]

“Previous studies have used gene therapy targeting selective regions ... However, neurodegenerative processes in LBD are more widespread than originally suspected therefore there is a need for therapeutic approaches that target toxic α-syn in multiple neuronal populations simultaneously.”

The study uses a transgenic mouse model with a treatment group (9E4 antibody) and a control group (IgG1). Key design elements like randomization method, randomization unit, and blinding levels are not reported. The Methods state 'All experiments were done blind-coded' but do not specify who was blinded or how allocation concealment was performed. No a priori power analysis is reported. The distinction between biological and technical replicates is not explicitly stated, though culture experiments were performed in triplicate. Inclusion criteria (α-syn tg mice, age 6 months) are stated, but no pre-specified exclusion criteria are mentioned. Outlier handling is not reported. Appropriate positive and negative controls are used (non-tg mice, IgG1 control). No independent replication of the core in vivo findings is reported outside the same experiment.

Sub-criteria

controlsADEQUATE

power analysisNOT REPORTED

blinding levelsINADEQUATE

outlier handlingNOT REPORTED

randomization unitNOT REPORTED

inclusion exclusionINADEQUATE

randomization methodNOT REPORTED

replicate distinctionNOT REPORTED

independent replicationNOT REPORTED

Per reviewer (3) — the votes behind the verdict

FAILReviewer 1· 95% conf

Critical design elements are missing: randomization method, blinding details, power analysis, inclusion/exclusion criteria, outlier handling, and independent replication are not reported or inadequately described.

Evidence

direct quote[Methods, 'Transgenic mouse model and passive immunization']

“A total of 40 α-syn tg mice (6 m/o, n = 20 mice per group) received weekly intraperitoneal (IP) injections (10 mg/kg) for 6 months with the CT-α-syn antibody (9E4) and IgG1 control.”

direct quote[Methods, 'Statistical analysis']

“All experiments were done blind-coded and in triplicate.”

absence[Methods, 'Transgenic mouse model and passive immunization']

No sample size justification is provided.

WARNReviewer 2· 90% conf

The study design has several strengths, including controls and behavioral testing, but lacks reporting on randomization, blinding details, and a priori power analysis.

Evidence

direct quote[Methods, Statistical analysis]

“All experiments were done blind-coded and in triplicate.”

absence[Methods]

No power analysis reported.

direct quote[Methods]

“A total of 40 α-syn tg mice (6 m/o, n = 20 mice per group) received weekly intraperitoneal (IP) injections (10 mg/kg) for 6 months with the CT-α-syn antibody (9E4) and IgG1 control. An additional group of non-tg mice treated with the 9E4 antibody (n = 12) and the IgG1 control (n = 12) was included as control for behavioral and neuropathological studies.”

WARNReviewer 3· 85% conf

The study design has strengths (control groups, behavioral and histological endpoints) but lacks a pre-specified power analysis, explicit randomisation method for the main study, and blinding details are incomplete.

Evidence

paraphrase[Methods, 'Transgenic mouse model and passive immunization']

“The text states 'A total of 40 α-syn tg mice (6 m/o, n = 20 mice per group) received weekly intraperitoneal (IP) injections ... with the CT-α-syn antibody (9E4) and IgG1 control' but does not describe how mice were allocated to groups.”

direct quote[Methods, 'Statistical analysis']

“All experiments were done blind-coded and in triplicate.”

direct quote[Methods, 'Transgenic mouse model and passive immunization']

“An additional group of non-tg mice treated with the 9E4 antibody (n = 12) and the IgG1 control (n = 12) was included as control for behavioral and neuropathological studies.”

The paper uses 6-month-old mice but does not report sex. As the study appears to be single-sex (implied by 'male' data from previous similar studies line D, but not stated), no justification for single-sex is given. Age (6 months old at start, 12 months at end) is reported. The species (mouse), strain/transgene (PDGF-β-α-syn, Line D), and source (UCSD breeding colony, implied) are reported. Health status is not reported. Housing conditions (light cycle, temperature, enrichment) are not reported. Demographics are not applicable (animal study).

Sub-criteria

demographicsN/A

sex reportedNOT REPORTED

sex justifiedNOT REPORTED

age weight healthINADEQUATE

housing conditionsNOT REPORTED

species strain sourceADEQUATE

Per reviewer (3) — the votes behind the verdict

FAILReviewer 1· 90% conf

Sex of mice is not reported, age is partially reported, weight and health status are omitted, housing conditions are not described, but strain and source are adequately reported.

Evidence

absence[Methods, 'Transgenic mouse model and passive immunization']

Sex of mice is not reported.

direct quote[Methods, 'Transgenic mouse model and passive immunization']

“A total of 40 α-syn tg mice (6 m/o, n = 20 mice per group)”

direct quote[Methods, 'Transgenic mouse model and passive immunization']

“For this study mice over-expressing α-syn under the PDGF-β promoter (Line D) were utilized.”

WARNReviewer 2· 85% conf

Sex and age are reported, but sex is not justified for a single-sex study, and health status, housing conditions, and demographics are not reported.

Evidence

absence[Methods, Transgenic mouse model and passive immunization]

Sex of mice is not reported anywhere in Methods or Results.

direct quote[Methods]

“A total of 40 α-syn tg mice (6 m/o, n = 20 mice per group) received weekly intraperitoneal (IP) injections (10 mg/kg) for 6 months”

absence[Methods]

Housing conditions are not described.

WARNReviewer 3· 80% conf

Sex of mice is not reported, and the paper does not specify if both sexes were used or justify a single-sex design. Age, strain, and source are adequately reported.

Evidence

absence[Methods, 'Transgenic mouse model and passive immunization' and throughout]

Sex of mice is not reported anywhere in the paper.

direct quote[Methods, 'Transgenic mouse model and passive immunization']

“A total of 40 α-syn tg mice (6 m/o, n = 20 mice per group) received weekly intraperitoneal (IP) injections ... For this study mice over-expressing α-syn under the PDGF-β promoter (Line D) were utilized.”

absence[Methods]

Housing conditions are not described.

The paper explicitly states that the experimental protocol was approved by the UCSD Animal Subjects Committee (protocol number S02221) and that the study was performed according to NIH recommendations and AAALAC guidelines.

Sub-criteria

iacuc statementADEQUATE

informed consentN/A

irb ethics statementN/A

regulatory complianceADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

Animal ethics approval is clearly stated with a named committee and protocol number, and regulatory compliance is mentioned.

Evidence

direct quote[Methods, 'Transgenic mouse model and passive immunization']

“All experiments described were approved by the animal subjects committee at the University of California at San Diego (UCSD) and were performed according to NIH recommendations for animal use. UCSD is an Institutional Animal Care and Use Committee accredited institution and the UCSD Animal Subjects Committee approved the experimental protocol ( S02221 )”

PASSReviewer 2· 95% conf

Ethical approval is properly reported with a named approving body and protocol number, and regulatory compliance is stated.

Evidence

direct quote[Methods, Transgenic mouse model and passive immunization]

PASSReviewer 3· 95% conf

The study provides a detailed animal ethics statement with a named approving body and protocol number, meeting adequacy criteria.

Evidence

direct quote[Methods, 'Transgenic mouse model and passive immunization']

Antibodies are identified by name and vendor (e.g., ELAN Pharmaceuticals, Millipore, Dako), and some catalog numbers are provided (e.g., for secondary antibodies and kits). However, RRIDs are not provided, and not all antibodies have catalog numbers or clone IDs (e.g., 'rabbit polyclonal' from Millipore lacks detail). The cell line B103 is identified by name only, with no source or authentication details (e.g., STR profiling or mycoplasma testing). The transgenic mouse line (Line D) is identified by description (PDGF-β-α-syn) and reference, but no RRID is given. Key reagents like LV-αsyn are described but not with full identification (e.g., plasmid source). Software tools (e.g., StereoInvestigator, ImageQuant, Noldus EthoVision) are named with vendor but without versions or RRIDs.

Sub-criteria

mycoplasma testingNOT REPORTED

reagents identifiedINADEQUATE

organisms identifiedINADEQUATE

antibodies identifiedINADEQUATE

cell line authenticationNOT REPORTED

software tools identifiedINADEQUATE

Per reviewer (3) — the votes behind the verdict

FAILReviewer 1· 90% conf

Many key resources are incompletely identified: antibodies lack catalog numbers, cell lines are not authenticated, no mycoplasma testing, reagents not fully specified, software versions missing. Only organism source is adequate.

Evidence

direct quote[Table 1]

“Table 1 Antibodies used for this study. Antibodyname Type of antibody Epitope/specificity Antibody Isotype ExperimentalUse 27-1 Monoclonal Control IgG1 Control for Immunization 6H7 Monoclonal NT 1-4 IgG1 Initial Characterization 8A5 Monoclonal CT 125-140 IgG1 InitialCharacterization 9E4 Monoclonal CT 118-126 IgG1 Passive Immunization”

direct quote[Methods, 'Neuronal cell cultures and treatments']

“The rat neuroblastoma cell line B103 was used for in vitro experiments.”

absence[Methods, 'Neuronal cell cultures and treatments']

Mycoplasma testing is not reported.

WARNReviewer 2· 85% conf

Key antibodies and reagents are partially identified with vendors, but clone/RRID, validation data, and full identification for all reagents are missing.

Evidence

direct quote[Methods, Table 1]

direct quote[Methods, Neuronal cell cultures and treatments]

“The rat neuroblastoma cell line B103 was used for in vitro experiments.”

direct quote[Methods, Behavioral testing, Immunocytochemical]

“Time to reach the platform (escape latency) was recorded with a Noldus Instruments EthoVision video tracking system (San Diego Instruments, San Diego, CA)”

WARNReviewer 3· 85% conf

Antibodies are well-characterized with epitopes and isotypes, but cell line authentication, mycoplasma testing, and full reagent identifiers (catalog numbers for many reagents) are missing, and software versions are incomplete.

Evidence

direct quote[Methods, 'Preparation of antibodies for passive immunization' and Table 1]

“Table 1 Antibodies used for this study. Antibodyname Type of antibody Epitope/specificity Antibody Isotype ExperimentalUse ... 9E4 Monoclonal CT 118-126 IgG1 Passive Immunization”

direct quote[Methods, 'Neuronal cell cultures and treatments']

“The rat neuroblastoma cell line B103 was used for in vitro experiments.”

direct quote[Methods, 'Immunocytochemical and neuropathological analyses']

“Stereological analysis and quantification ... was conducted by the disector method using the Stereo-Investigator System (MBF Bioscience, Williston, VT)”

The paper names the statistical tests (one-way ANOVA, repeated-measures two-way ANOVA, post-hoc Dunnett's, Tukey-Kramer, Fisher). However, it does not report exact p-values (uses 'p<0.05' or asterisks) nor effect sizes or confidence intervals. No verification of test assumptions (normality, equal variance) is reported. Statistical software is identified (StatView, not named in the paper text). Data presentation includes per-group N, error bars (SEM), and individual data points are not shown per se but bar graphs with error bars and individual data points in some figures (e.g., Figure 1A). No arithmetic checks are possible from the aggregate data presented. The scoring rule for this dimension is met with 30-59% adequate. Mathematical plausibility is not_applicable given the data presentation.

Sub-criteria

tests namedADEQUATE

exact p valuesINADEQUATE

effect sizes ciNOT REPORTED

data presentationINADEQUATE

software identifiedNOT REPORTED

assumptions verifiedNOT REPORTED

mathematical plausibilityN/A

Per reviewer (3) — the votes behind the verdict

FAILReviewer 1· 95% conf

Statistical tests are named, but assumptions are not verified, exact p-values are not reported, effect sizes and confidence intervals are missing, software is not identified, and data presentation uses bar graphs without individual data points.

Evidence

direct quote[Methods, 'Statistical analysis']

“Values were compared using one-way analysis of variance (ANOVA) with post hoc Dunnett's test when comparing to the IgG1 control.”

direct quote[Methods, 'Statistical analysis']

“The differences were considered to be significant if p values were less than 0.05.”

absence[Methods, 'Statistical analysis']

Statistical software is not identified.

WARNReviewer 2· 85% conf

Statistical tests are named, but key details like exact p-values, effect sizes, and assumptions verification are missing, and data presentation is adequate for the study type.

Evidence

direct quote[Methods, Statistical analysis]

“Values in the figures are expressed as means ± SEM. To determine the statistical significance, values were compared using one-way analysis of variance (ANOVA) with post hoc Dunnett's test when comparing to the IgG1 control. Additional comparisons were done using Tukey-Kramer or Fisher post hoc tests. Repeated-measures two-way ANOVA was used to analyze the water maze and Rotarod data when comparing immunized mice to the non-tg or IgG1 treated controls. The differences were considered to be significant if p values were less than 0.05.”

direct quote[Results and Figure Legends]

“(*) indicates p<0.05, when comparing α-syn tg immunized with IgG1 to non-tg group by one-way ANOVA with post hoc Dunnett's and (#) indicates p<0.05, when comparing α-syn tg immunized with 9E4 to IgG1 immunized α-syn tg mice by one-way ANOVA with post hoc Dunnett's.”

absence[Methods, Statistical analysis]

No statistical software is named in the Methods.

WARNReviewer 3· 75% conf

Statistical tests are named and appropriate, but exact p-values are not reported (only thresholds like p<0.05), effect sizes/confidence intervals are absent, and assumptions (normality, homoscedasticity) are not verified.

Evidence

direct quote[Methods, 'Statistical analysis']

“The differences were considered to be significant if p values were less than 0.05.”

direct quote[Figure 1 legend]

“Error bars represent mean ± SEM.”

absence[Methods, 'Statistical analysis']

Assumptions for ANOVA are not verified.

The paper does not contain a data availability statement. The data (behavioral scores, immunohistochemistry, immunoblots) are not deposited in a public repository. No custom code is mentioned, but the statistical software and analysis methods are described in the text. For an animal study, data sharing is expected, but the absence of a statement is a reporting gap. All four sub-criteria are reported_but_inadequate or not_reported.

Sub-criteria

code sharingN/A

accession numbersNOT REPORTED

repository depositNOT REPORTED

data availability statementNOT REPORTED

Per reviewer (3) — the votes behind the verdict

FAILReviewer 1· 95% conf

No data availability statement, no repository deposit, no accession numbers, and no code sharing are reported.

Evidence

absence[Entire paper]

No data availability statement.

absence[Entire paper]

No repository deposit.

WARNReviewer 2· 90% conf

A data availability statement is absent, so no data or code are publicly accessible, though a statement is expected for any study.

Evidence

absence[Endmatter]

No data availability statement is present in the paper.

absence[Discussion and Methods]

No repository deposit is mentioned.

absence[Methods]

No code is described as shared or available.

WARNReviewer 3· 90% conf

No data availability statement is provided, and no data or code repositories are mentioned. The paper does not share raw data or custom code.

Evidence

absence[Methods, Results, Discussion, Competing Interests]

No data availability statement is present.

absence[Throughout paper]

No data repository or accession numbers are mentioned.

absence[Throughout paper]

No custom code repository is cited.

The methods are detailed enough for replication, though some specifics like randomization and blinding are missing. For a preclinical study, trial registration is not applicable. No reporting guideline (e.g., ARRIVE) is mentioned. All outcomes described in the Methods are reported, but negative results (e.g., no effect on tau) are reported. Limitations are not discussed in a dedicated section, though some caveats are implied. Conclusions are generally proportional to the evidence, but the claim that the antibody 'traffics into the CNS' is supported. Funding and conflicts of interest are transparently provided.

Sub-criteria

funding coiADEQUATE

trial registrationN/A

reporting guidelineNOT REPORTED

methods completenessINADEQUATE

all outcomes reportedINADEQUATE

limitations discussedNOT REPORTED

conclusions proportionalADEQUATE

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 80% conf

Methods are partially detailed, reporting guidelines are not referenced, and limitations are not discussed, but all outcomes appear reported, conclusions are proportional to the evidence, and funding and conflicts of interest are disclosed.

Evidence

absence[Methods, entire section]

No reporting guidelines referenced.

absence[Discussion, entire section]

Limitations are not discussed.

direct quote[End of manuscript]

“Funding: This work was funded by National Institutes of Health (NIH) grants ... and by ELAN Pharmaceuticals. Competing Interests: The authors have declared the following conflict of interest: ...”

WARNReviewer 2· 85% conf

Methods are mostly complete, but the paper lacks a completed reporting checklist, all outcomes (including negative results) are not fully transparent, and a limitations section is missing.

Evidence

absence[Methods]

No reporting guideline (e.g., ARRIVE) is referenced.

absence[Discussion]

Limitations are not discussed in a dedicated section.

direct quote[Funding and Competing Interests sections]

“Funding: This work was funded by National Institutes of Health (NIH) grants AG 11385, AG 18840, AG 022074 and NS 044233 and by ELAN Pharmaceuticals. NIH had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

WARNReviewer 3· 80% conf

Methods are described in detail, limitations are discussed, and conclusions are proportional. However, no trial registration (n/a for preclinical), no reporting guideline checklist referenced, and funding/COI are stated.

Evidence

paraphrase[Methods, subsections]

“The Methods section includes detailed descriptions of the transgenic mouse model, antibody preparation, behavioral testing (water maze, pole test, rotarod), and neuropathological analyses.”

paraphrase[Introduction and Discussion]

“The introduction notes that mechanisms of α-syn immunotherapy are unclear and that it is unknown what triggers aggregation in sporadic LBD.”

direct quote[Competing Interests and Funding sections]

“This work was funded by National Institutes of Health (NIH) grants AG 11385, AG 18840, AG 022074 and NS 044233 and by ELAN Pharmaceuticals.”

20 copyedit issues flagged: mostly typo, consistency, grammar.

Checked 63 references: 55 verified — 2 retracted, 6 not checked.

Αlpha¹ Rigor Action ItemsFinal pass before journal submission

POST-PUBLICATION AUDIT: This published paper has substantial reporting deficiencies that an informed reader should weigh heavily. The absence of randomization, blinding, and sex/housing details, incomplete resource identification, missing exact p-values and effect sizes, lack of a data availability statement, and two retracted citations collectively limit the ability to assess the robustness and generalizability of the findings. A formal correction or independent re-analysis addressing these issues is warranted; the paper should not be taken at face value without these clarifications.

1.
HIGHother
Remove or replace the two retracted citations (PLoS ONE 2009;4(12):e9313 and PLoS ONE 2008;3(9):e3135) with non-retracted references in the manuscript.
Citing retracted papers undermines the integrity of the literature review; authors should verify and correct these references in an erratum.
2.
HIGHreporting
Temper the claim that 'passive immunization with 9E4 is a potential therapeutic alternative for patients with Parkinson's disease and dementia with Lewy bodies' to reflect that the evidence is only from a transgenic mouse model and in vitro systems; add explicit mention of the limitations of preclinical models.
Overstating clinical implications from animal data is a common source of misinterpretation; the conclusion should be constrained to the model system studied.
3.
HIGHdata code
Add a data availability statement specifying where raw data can be accessed (e.g., a repository like Dryad or Figshare) or provide a mechanism for data sharing upon request; if possible, deposit the primary data.
Without a data availability statement, the reproducibility of the findings cannot be verified by other researchers.
4.
HIGHrigor
Describe the randomization method (e.g., random number generator) and unit of randomization (individual mouse or cage) in the Methods, 'Transgenic mouse model and passive immunization' section.
Randomization is essential to minimize selection bias; its absence is a major methodological gap.
5.
HIGHrigor
Detail blinding procedures: specify who was blinded (experimenter, assessor, data analyst) and at which stages (treatment allocation, behavioral testing, histological analysis) in the Statistical analysis section.
Blinding prevents performance and detection bias; the current vague statement ('blind-coded') is insufficient.
6.
HIGHrigor
Report the sex of mice used; if only one sex was used, provide a scientific justification for why both sexes were not included.
Sex is a fundamental biological variable; unreported sex compromises the generalizability and reproducibility of the findings.
7.
HIGHrigor
Describe housing conditions (light-dark cycle, temperature, humidity, enrichment) for the mice in the Methods section.
Housing conditions can affect behavior and physiology; their absence limits interpretation of the behavioral results.
8.
HIGHrigor
Report exact p-values (e.g., p = 0.023) instead of threshold statements ('p < 0.05') throughout the Results and figure legends.
Exact p-values allow readers to judge the strength of evidence, whereas threshold-only reporting is imprecise.
9.
HIGHstatistics
Include effect sizes (e.g., Cohen's d, partial η²) and 95% confidence intervals for all primary comparisons in the Results.
Effect sizes and confidence intervals provide information on the magnitude and precision of effects, which p-values alone do not.
10.
HIGHstatistics
Identify the statistical software used (e.g., GraphPad Prism, SPSS, R) with version number in the Statistical analysis section.
Software and version identification is needed for methodological reproducibility; its absence is a reporting gap.
11.
HIGHrigor
Provide vendor catalog numbers and/or RRIDs for all commercial antibodies and reagents in Table 1 and the Methods.
Without resource identifiers, other laboratories cannot precisely replicate the experimental conditions.
12.
HIGHrigor
Include a statement on cell line authentication (e.g., STR profiling) and mycoplasma testing for the B103 cell line in the Neuronal cell cultures section.
Uncharacterized cell lines can yield irreproducible results; authentication and contamination testing are standard requirements.
13.
MEDIUMreporting
Add a dedicated Limitations section in the Discussion addressing the use of a single transgenic line, potential off-target effects of immunotherapy, lack of independent replication, and the translational gap between mice and humans.
A transparent limitations section helps readers appropriately contextualize the findings and is expected by journals.
14.
MEDIUMreporting
Reference the ARRIVE 2.0 guidelines for animal research in the Methods.
Adherence to reporting guidelines improves completeness and is increasingly mandated by journals and funders.
15.
MEDIUMrigor
Perform and report an a priori power analysis to justify the sample sizes, citing the expected effect size, alpha, and power.
Sample size justification is critical to ensure the study is adequately powered to detect meaningful effects.
16.
MEDIUMrigor
Pre-specify inclusion/exclusion criteria for mice (e.g., health status, baseline behavioral performance) and state how outliers were handled (e.g., pre-defined threshold for exclusion).
Without pre-specified criteria, post hoc exclusions can introduce bias and reduce confidence in the results.
17.
MEDIUMrigor
Clearly distinguish biological and technical replicates in the Methods, particularly for the in vitro cell culture experiments.
Confusing biological with technical replicates inflates effective sample sizes and can lead to false conclusions.
18.
MEDIUMrigor
Report software versions (e.g., StereoInvestigator 10.0, EthoVision XT) in the Methods.
Software version is necessary for reproducibility; different versions can produce different results.
19.
LOWcopyedit
Fix typos throughout: 'sacrified' -> 'sacrificed', 'niave' -> 'naive', 'arbitary' -> 'arbitrary'.
Simple typos detract from the professionalism of the manuscript.
20.
LOWcopyedit
Standardize the notation of α-synuclein: use 'α-syn' consistently instead of mixing 'a-syn' and 'α-syn'.
Inconsistent terminology can confuse readers.
21.
LOWcopyedit
Rewrite the awkward sentence in the Methods, 'Transgenic mouse model and passive immunization': 'For this experiment non-tg (total n = 18) and α-syn tg mice (total n = 18) (6 m/o) were injected intravenously (IV) with the 9E4-FITC or a non-immune control FITC tagged IgG1 at a concentration of 1 mg/kg.' for clarity; also fix the duplicated fragment starting with 'For this experiment'.
Awkward phrasing and duplicated text reduce readability.
22.
LOWcopyedit
Correct grammatical errors: fix run-on sentence in the Results regarding tau data (use semicolon or period before 'in contrast'), and fix verb agreement ('cathepsin-D was detected' -> 'cathepsin D were detected').
Grammar errors can obscure meaning and reflect poorly on the authors' attention to detail.

Full text (89,668 chars · analyzed ~84%, head + tail)Analyzed: Jul 6, 2026

Αlpha¹ assesses methodological rigor, not the importance of the findings. See how we calibrate →